» Articles » PMID: 34531443

Real-time Quantitation of Thyroidal Radioiodine Uptake in Thyroid Disease with Monitoring by a Collar Detection Device

Overview
Journal Sci Rep
Specialty Science
Date 2021 Sep 17
PMID 34531443
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Radioactive iodine (RAI) is safe and effective in most patients with hyperthyroidism but not all individuals are cured by the first dose, and most develop post-RAI hypothyroidism. Postoperative RAI therapy for remnant ablation is successful in 80-90% of thyroid cancer patients and sometimes induces remission of nonresectable cervical and/or distant metastatic disease but the effective tumor dose is usually not precisely known and must be moderated to avoid short- and long-term adverse effects on other tissues. The Collar Therapy Indicator (COTI) is a radiation detection device embedded in a cloth collar secured around the patient's neck and connected to a recording and data transmission box. In previously published experience, the data can be collected at multiple time points, reflecting local cervical RAI exposure and correlating well with conventional methods. We evaluated the real-time uptake of RAI in patients with hyperthyroid Graves' disease and thyroid cancer. We performed a pilot feasibility prospective study. Data were analyzed using R (version 4.0.3, The R Foundation for Statistical Computing, 2020), and Python (version 3.6, Matplotlib version 3.0.3). The COTI was able to provide a quantitative temporal pattern of uptake within the thyroid in persons with Graves' disease and lateralized the remnant tissue in persons with thyroid cancer. The study has demonstrated that the portable collar radiation detection device outside of a healthcare facility is accurate and feasible for use after administration of RAI for diagnostic studies and therapy to provide a complete collection of fractional target radioactivity data compared to that traditionally acquired with clinic-based measurements at one or two time-points.Clinical Trials Registration NCT03517579, DOR 5/7/2018.

Citing Articles

Understanding the factors of wearable devices among the patients with thyroid cancer: A modified UTAUT2 model.

Song L, Li B, Wu H, Wu C, Zhang X PLoS One. 2024; 19(7):e0305944.

PMID: 39058689 PMC: 11280220. DOI: 10.1371/journal.pone.0305944.


Investigation of the Suitability of a Commercial Radiation Sensor for Pretherapy Dosimetry of Radioiodine Treatment Patients.

OCallaghan J, Cody D, Cooke J Sensors (Basel). 2022; 22(23).

PMID: 36502094 PMC: 9739645. DOI: 10.3390/s22239392.

References
1.
Watanabe M, Ito K, Mimura T, Ishikawa N, Ino E, Saitoh T . [Estimation of effective half life of 131I in radioiodine therapy for Graves' disease using a single radioiodine uptake measurement]. Kaku Igaku. 1993; 30(9):1055-62. View

2.
Gibb F, Zammitt N, Beckett G, Strachan M . Predictors of treatment failure, incipient hypothyroidism, and weight gain following radioiodine therapy for Graves' thyrotoxicosis. J Endocrinol Invest. 2013; 36(9):764-9. DOI: 10.3275/8949. View

3.
Moura-Neto A, Mosci C, Santos A, Amorim B, de Lima M, Etchebehere E . Predictive factors of failure in a fixed 15 mCi 131I-iodide therapy for Graves' disease. Clin Nucl Med. 2012; 37(6):550-4. DOI: 10.1097/RLU.0b013e31824851d1. View

4.
Osaki Y, Sakurai K, Arihara Z, Hata M, Fukazawa H . Prediction of late (24-hour) radioactive iodine uptake using early (3-hour) uptake values in Japanese patients with Graves' disease. Endocr J. 2011; 59(2):173-7. DOI: 10.1507/endocrj.ej11-0279. View

5.
Brinks P, van Gils K, Kranenborg E, Lavalaye J, Dieckens D, Habraken J . Measuring the actual I-131 thyroid uptake curve with a collar detector system: a feasibility study. Eur J Nucl Med Mol Imaging. 2016; 44(6):935-940. DOI: 10.1007/s00259-016-3595-y. View